# CytoReason Abstract

**Investment Rational**
CytoReason is a tech company developing computational disease models. Its proprietary database and AI-led platform helps pharma and biotech companies reduce the cost, time, and complexity of bringing new therapies to market. To date, five of the world's top ten pharma companies, including Pfizer and Sanofi, use CytoReason's technology.

**Investment Rational**
CytoReason equips pharma and biotech companies with technology suitable for the era of precision medicine, while enhancing their drug pipeline. In the short-term, our collaborative partnerships empower drug makers to address multiple use cases using our AI platform. In the long-term, our joint ventures with pharma and biotech companies shepherd the drug development lifecycle, from early development all the way to post-market.

**Core Technology**
CytoReason's computational disease models are organized in a cloud-based platform, bringing together big data with cutting-edge algorithms. The platform sorts and standardizes human molecular data of DNA, mRNA, proteins, and cells, from multiple data sources. The models simplify complex molecular mechanisms, making them understandable to researchers of all levels in the organization. The platform helps customers dissect the drug landscape and compare their treatments to others in the market.

**Product Profile/Pipeline**
CytoReason's platform changes drug development from trial and error to a predictable data-driven practice. It removes data inconsistency and empowers program managers to merge research efforts and deliver comparative results. The platform currently hosts multiple disease models and serves pharma companies such as Pfizer, and biotech companies such as Poolbeg. We're constantly adding disease models to the platform and integrating customer data in the user interface.

**What's Next?**
Looking ahead, we plan to partner with payers on risk-sharing contracts and with CROs on clinical trial insurance. We'll hire more engineers and scientists to augment our pool of 70 employees, and add features to our platform and comparisons to our disease models. As we expand to additional therapeutic areas and diversify data types, we aim to establish our platform as the gold standard for drug portfolio management.